These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 28904877)

  • 1. Long-term repeated rituximab treatment for childhood steroid-dependent nephrotic syndrome.
    Kim JH; Park E; Hyun HS; Cho MH; Ahn YH; Choi HJ; Kang HG; Ha IS; Cheong HI
    Kidney Res Clin Pract; 2017 Sep; 36(3):257-263. PubMed ID: 28904877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
    Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
    BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of long-term repeated use of rituximab in pediatric patients with nephrotic syndrome.
    Choi N; Min J; Kim JH; Kang HG; Ahn YH
    Pediatr Nephrol; 2024 Mar; 39(3):771-780. PubMed ID: 37682369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive factors of long-term disease remission after rituximab administration in patients with childhood-onset complicated steroid-dependent nephrotic syndrome: a single-center retrospective study.
    Ohyama R; Fujinaga S; Sakuraya K; Hirano D; Ito S
    Clin Exp Nephrol; 2023 Oct; 27(10):865-872. PubMed ID: 37477752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
    Fujinaga S; Hirano D; Mizutani A; Sakuraya K; Yamada A; Sakurai S; Shimizu T
    Clin Exp Nephrol; 2017 Aug; 21(4):671-676. PubMed ID: 27558467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome.
    Tellier S; Brochard K; Garnier A; Bandin F; Llanas B; Guigonis V; Cailliez M; Pietrement C; Dunand O; Nathanson S; Bertholet-Thomas A; Ichay L; Decramer S
    Pediatr Nephrol; 2013 Jun; 28(6):911-8. PubMed ID: 23340857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab in childhood steroid-sensitive nephrotic syndrome: are multiple subsequent courses safe and effective?
    Subun C; Suwannahitatorn P; Webb H; Tullus K
    Arch Dis Child; 2021 Jul; 106(8):815-818. PubMed ID: 33177054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab in children with steroid-dependent nephrotic syndrome: experience of a tertiary center and review of the literature.
    Van Horebeek I; Knops N; Van Dyck M; Levtchenko E; Mekahli D
    Acta Clin Belg; 2017 Jun; 72(3):147-155. PubMed ID: 27409338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single dose of rituximab in children with steroid-dependent minimal change nephrotic syndrome.
    Niu XL; Hao S; Wang P; Zhang W; Guo GM; Wu Y; Kuang XY; Zhu GH; Huang WY
    Biomed Rep; 2016 Aug; 5(2):237-242. PubMed ID: 27446549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab.
    Kamei K; Ogura M; Sato M; Sako M; Iijima K; Ito S
    Pediatr Nephrol; 2016 Jan; 31(1):89-95. PubMed ID: 26341251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and safety of low-dose rituximab in treatment of pediatric nephrotic syndrome: a prospective randomized controlled trial].
    Zhu Y; Wu L; Wang Y; Zhu YF; Peng Y; Fang SH; Zhang LD; Deng F
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 Jun; 25(6):606-611. PubMed ID: 37382130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel use of rituximab for steroid-dependent nephrotic syndrome in children.
    Kimata T; Hasui M; Kino J; Kitao T; Yamanouchi S; Tsuji S; Kaneko K
    Am J Nephrol; 2013; 38(6):483-8. PubMed ID: 24296765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idiopathic nephrotic syndrome and rituximab: may we predict circulating B lymphocytes recovery?
    Delbet JD; Leclerc G; Ulinski T
    Pediatr Nephrol; 2019 Mar; 34(3):529-532. PubMed ID: 30542932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood--follow-up after CD19 recovery.
    Sellier-Leclerc AL; Baudouin V; Kwon T; Macher MA; Guérin V; Lapillonne H; Deschênes G; Ulinski T
    Nephrol Dial Transplant; 2012 Mar; 27(3):1083-9. PubMed ID: 21810762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Efficacy and Safety of Rituximab for Childhood Steroid-Dependent Nephrotic Syndrome: A Systematic Review and Meta-Analysis.
    Liu S; Gui C; Lu Z; Li H; Fu Z; Deng Y
    Front Pediatr; 2021; 9():728010. PubMed ID: 34490171
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome.
    Hogan J; Dossier C; Kwon T; Macher MA; Maisin A; Couderc A; Niel O; Baudouin V; Deschênes G
    Pediatr Nephrol; 2019 Feb; 34(2):253-259. PubMed ID: 30109447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study.
    Takahashi T; Okamoto T; Sato Y; Yamazaki T; Hayashi A; Aoyagi H; Ueno M; Kobayashi N; Uetake K; Nakanishi M; Ariga T
    Pediatr Nephrol; 2019 Jan; 34(1):87-96. PubMed ID: 30141179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab therapy in adults with steroid-dependent nephrotic syndrome.
    Zhong H; Li HY; Zhou T; Weng W
    Arch Med Sci; 2023; 19(3):577-585. PubMed ID: 37313189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of rituximab therapy in children with nephrotic syndrome: a 10-year experience from an Iranian pediatric hospital.
    Bazargani B; Noparast Z; Khedmat L; Fahimi D; Esfahani ST; Moghtaderi M; Abbasi A; Afshin A; Mojtahedi SY
    BMC Pediatr; 2022 Jan; 22(1):36. PubMed ID: 35022016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The outcome of rituximab in treating steroid dependent nephrotic syndrome.: Histopathology and immunosuppressive drugs as predicting factors.
    Al Salloum AA; Al Herbish AJ; Al Hissi MA; Abdalla MS; Salim SB; Farhat AH; Shagal RA; Othman A; Alshaiban A; Temsah MA; Al-Eyadhy AA; Alhasan KA
    Saudi Med J; 2022 Jul; 43(7):760-764. PubMed ID: 35830996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.